Machine learning in medicine

A Rajkomar, J Dean, I Kohane - New England Journal of …, 2019 - Mass Medical Soc
Machine Learning in Medicine In this view of the future of medicine, patient–provider
interactions are informed and supported by massive amounts of data from interactions with …

Clonal expansion in non-cancer tissues

N Kakiuchi, S Ogawa - Nature Reviews Cancer, 2021 - nature.com
Cancer is a clonal disorder derived from a single ancestor cell and its progenies that are
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …

On the opportunities and risks of foundation models

R Bommasani, DA Hudson, E Adeli, R Altman… - arXiv preprint arXiv …, 2021 - arxiv.org
AI is undergoing a paradigm shift with the rise of models (eg, BERT, DALL-E, GPT-3) that are
trained on broad data at scale and are adaptable to a wide range of downstream tasks. We …

Life histories of myeloproliferative neoplasms inferred from phylogenies

N Williams, J Lee, E Mitchell, L Moore, EJ Baxter… - Nature, 2022 - nature.com
Mutations in cancer-associated genes drive tumour outgrowth, but our knowledge of the
timing of driver mutations and subsequent clonal dynamics is limited,–. Here, using whole …

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

KL Bolton, RN Ptashkin, T Gao, L Braunstein… - Nature …, 2020 - nature.com
Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

EJ Duncavage, A Bagg, RP Hasserjian… - Blood, The Journal …, 2022 - ashpublications.org
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic
cells driven by somatic gene mutations. Although assessment of morphology plays a crucial …

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

E Bernard, Y Nannya, RP Hasserjian, SM Devlin… - Nature medicine, 2020 - nature.com
Abstract Tumor protein p53 (TP53) is the most frequently mutated gene in cancer,. In
patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high …

Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes

M Bersanelli, E Travaglino, M Meggendorfer… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Recurrently mutated genes and chromosomal abnormalities have been
identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features …

Genetics of MDS

S Ogawa - Blood, The Journal of the American Society of …, 2019 - ashpublications.org
Our knowledge about the genetics of myelodysplastic syndromes (MDS) and related
myeloid disorders has been dramatically improved during the past decade, in which …

[HTML][HTML] Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms

D Van Egeren, J Escabi, M Nguyen, S Liu, CR Reilly… - Cell stem cell, 2021 - cell.com
Some cancers originate from a single mutation event in a single cell. Blood cancers known
as myeloproliferative neoplasms (MPNs) are thought to originate when a driver mutation is …